Innovation in bone healing and tissue repair

KUR-112 is a parathyroid hormone-fibrin-based product. It is intended to be applied as a single percutaneous injection into solitary bone cysts and could therefore become a simpler, minimally invasive treatment for this rare condition.

KUR-112 has received Orphan Drug Designation in the US and Europe, which entitles the sponsor to receive assistance in the development process, exemption from application fees and several years of marketing exclusivity following approval. In October 2016, the US Food and Drug Administration granted Rare Pediatric Disease Designation.

The program has completed non-clinical testing. Kuros is currently evaluating the development options for KUR-112.

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    Spinal fusion
    KUR-113
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Fibrin-based
  3. Synthetic-based
  4. Immune modulation
  5. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
KUR-112

KUR-112 is a parathyroid hormone-fibrin-based product. It is intended to be applied as a single percutaneous injection into solitary bone cysts and could therefore become a simpler, minimally invasive treatment for this rare condition.

KUR-112 has received Orphan Drug Designation in the US and Europe, which entitles the sponsor to receive assistance in the development process, exemption from application fees and several years of marketing exclusivity following approval. In October 2016, the US Food and Drug Administration granted Rare Pediatric Disease Designation.

The program has completed non-clinical testing. Kuros is currently evaluating the development options for KUR-112.